nach oben

International Journal of Colorectal Disease

Erschienen in:

01.01.2004 | Original Article

Molecular lesions in colorectal cancer: impact on prognosis?

Original data and review of the literature

verfasst von: B. Klump, O. Nehls, T. Okech, C.-J. Hsieh, V. Gaco, F. S. Gittinger, M. Sarbia, F. Borchard, A. Greschniok, H. H. Gruenagel, R. Porschen, M. Gregor

Erschienen in: International Journal of Colorectal Disease | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

Background

In the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease. Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance.

Discussion

One also hopes to derive improved prognostic factors from the clarification of the molecular pathogenesis. Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors. Despite a multitude of suggested molecular candidate markers none of these changes has yet been able enter the everyday life of the clinic. However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma.

Conclusion

Considering also our own findings, this review presents the latest developments in the scientific discussion of the tumor suppressor/oncogenes p53, k-ras, and DCC, biochemical determinants of the 5-fluorouracil metabolism, and defects of the DNA repair system.

Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981–1990. Springer, Berlin Heidelberg New York

Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics. CA Cancer J Clin 47:5–27PubMed

Dukes CE, Bussey HJR (1958) The spread of rectal cancer and its effect on prognosis. Br J Cancer 12:309–320

Fielding LP (1986) Clinical-pathologic staging of large bowel cancer. Lancet 45:8–30

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358PubMed

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection for stage III colon carcinoma: a final report. Ann Intern Med 122:321–326PubMed

Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767PubMed

Fearon ER (1995) Molecular genetics of colorectal cancer. Ann N Y Acad Sci 768:101–110PubMed

Jen J, Kim H, Piantadosi S, Liu ZF, Liu ZF, Levitt RC, Sistonen P, et al (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213–221PubMed

10.

Levine AJ, Momand J, Finlay CA (1991) The p53 tumor suppressor gene. Nature 351:453–456PubMed

11.

Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318–1327CrossRefPubMed

12.

Chang F, Syrjanen S, Syrjanen K (1995) Implications of the p53-tumor-suppressor gene in clinical oncology. J Clin Oncol 4:1009–1022

13.

Pereira H, Silva S, Juliao R, Garcia P, Perpetua F, et al (1997) Prognostic markers for colorectal cancer: expression of p53 and bcl2. World J Surg 21:210–213CrossRefPubMed

14.

Smith DR, Ji CY, Goh HS (1996) Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 74:216–223

15.

Soong R, Grieu F, Robbins P, et al (1997) p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405–1411PubMed

16.

Elsaleh H, Powell B, McCaul K, et al (2001) P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7:1343–1349PubMed

17.

Esteller M, González S, Risques RA, et al (2001) k-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 19:299–304PubMed

18.

Yang Y, Forslund A, Remotti, et al (2001) P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 91:727–736CrossRefPubMed

19.

Gervaz P, Bouzourene H, Cerottini J-P, et al (2001) Dukes B colorectal cancer. Distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 44:364–373PubMed

20.

Diez M, Medrano M, Muguerza JM, et al (2000) Influence of tumor localization on the prognostic value of p53 protein in colorectal adenocarcinomas. Anticancer Res 20:3907–3912PubMed

21.

Gallego MG, Acenero MJ, Ortega S, et al (2000) Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 43:971–975

22.

Bouzourene H, Gervaz P, Cerottini JP, et al (2000) P53 and k-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36:1008–1015CrossRefPubMed

23.

Nehls O, Klump B, Holzmann K, et al (1999) Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. Cancer 85:2541–2548

24.

Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, et al (1999) Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 17:593–599

25.

Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al (1999) Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17:1364–1374PubMed

26.

Tollenaar RAEM, van Krieken JHJM, van Slooten HJ, Bruinvels DJ, Nelemans KMJ, van den Broek LJ, et al (1998) Immunohistochemical detection of p53 and BCL-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer 77:1842–1847PubMed

27.

Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, et al (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58:1149–1158PubMed

28.

Ilyas M, Hao X-P, Wilkinson K, et al (1998) Loss of bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 43:383–387PubMed

29.

Wiggenraad R, Tamminga R, Blok P, et al (1998) The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 41:29–35PubMed

30.

Caldes T, Iniesta P, de Juan C, et al (1998) Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer. Oncology 55:249–257CrossRefPubMed

31.

Starzynska T, Bromley M, Marlicz K, Roberts SA, Ucinski M, Stern PL (1997) Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma. Eur J Gastroenterol Hepat 9:183–186

32.

Maeda K, Chung Y-S, Kang S-M, et al (1997) Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74:310–315CrossRefPubMed

33.

Poller DN, Baxter KJ, Shepherd NA (1997) P53 and RB1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 75:87–93

34.

Bhatavdekar JM, Patel DD, Ghosh N, et al (1997) Coexpression of bcl-2, c-myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40:785–790PubMed

35.

Baretton GB, Diebold J, Christoforis G, et al (1996) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77:255–264CrossRefPubMed

36.

Flamini G, Curigliano G, Ratto C, et al (1996) Prognostic significance of cytoplasmatic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer 32A:802–806CrossRefPubMed

37.

Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, et al (1996) P53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14:2696–2701PubMed

38.

Leahy DT, Salman R, Mulcahy H, et al (1996) Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 180:364–370CrossRefPubMed

39.

Mulder JWR, Baas IO, Polak MM, Goodman SN, Offerhaus GJA (1995) Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 71:1257–1262

40.

Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, et al (1995) Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:647–652PubMed

41.

Diez M, Enriquez JM, Camunas J, et al (1995) Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. Eur J Surg Oncol 21:635–639PubMed

42.

Grewal H, Guillem JG, Klimstra DS, et al (1995) P53 nuclear overexpression may not be an independent prognostic marker in early colorectal cancer. Dis Colon Rectum 38:1176–1181PubMed

43.

Auvinen A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M (1994) Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 70:293–296PubMed

44.

Bosari S, Viale G, Bossi P, et al (1994) Cytoplasmatic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86:681–687PubMed

45.

Morrin M, Kelly M, Barrett N, Delaney P (1994) Mutations of ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 35:1627–1631PubMed

46.

Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT (1994) Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 37:527–534PubMed

47.

Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, et al (1994) P53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 12:2043–2050PubMed

48.

Tanaka M, Omura K, Watanabe Y, Oda Y, Nakanishi I (1994) Prognostic factors of colorectal cancer: k-ras mutation, overexpression of the p53 protein, and cell proliferative activity. J Surg Oncol 57:57–64PubMed

49.

Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y, Miyazaki I (1993) p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68:399–402PubMed

50.

Bell S, Scott N, Cross D, Sagar P, Lewis FA, Blair E, et al (1993) Prognostic value of p53 overexpression and c-ki-ras gene mutations in colorectal cancer. Gastroenterology 104:57–64PubMed

51.

Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P (1991) P53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63:317–319PubMed

52.

Remvikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, et al (1992) Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 66:758–764

53.

Rosty C, Chazal M, Etienne M-C, et al (2001) Determination of microsatellite instability, p53 and k-ras mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer 95:162–167

54.

Bleeker WA, Hayes VM, Karrenbeld A, et al (2001) Prognostic significance of k-ras and p53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum 44:358–363PubMed

55.

Soong R, Powell B, Elsaleh H, et al (2000) Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36:2053–2060CrossRefPubMed

56.

Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA, et al (2000) P53 tumor supressor gene mutations predict decreased survival with sporadic colorectal carcinoma. Cancer 88:1814–1819CrossRefPubMed

57.

Liang JT, Cheng YM, Chang KJ, Chien CT, Hsu HC (1999) Reappraisal of k-ras and p53 gene mutations in the recurrence of Dukes B2 rectal cancer after curative resection. Hepatogastroenterology 46:830–837

58.

Tortola S, Marcuello E, Gonzalez I, Reyes G, Arribas R, Aiza G, et al (1999) P53 and k-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 17:1375–1381PubMed

59.

Hardingham JE, Butler WJ, Roder D, Dobrovic A, Dymock RB, Sage RE, et al (1998) Somatic mutations, acetylator status, and prognosis in colorectal cancer. Gut 42:669–672PubMed

60.

Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al (1994) Association of p53 mutations with short term survival in colorectal cancer. Gastroenterology 106:42–48PubMed

61.

Baas IO, Mulder JWR, Offerhaus GJA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12PubMed

62.

Dix B, Robbins P, Carello A, House A, Iacopetta B (1994) Comparison of p53 gene mutation and protein overexpression in colorectal carcinoma. Br J Cancer 70:585–590

63.

Wynford-Thomas D (1992) P53 in tumor pathology: can we trust immunocytochemistry? J Pathol 166:329

64.

Barbacid M (1987) Ras genes. Annu Rev Biochem 56:779–827PubMed

65.

Lee JC, Wang ST, Lai MD, Lin YJ, Yang HB (1996) k-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 16:3839–3844PubMed

66.

Font A, Abad A, Monzo M, Sanchez JJ, Guillot M, Manzano JL, et al (2001) Prognostic value of k-ras mutations and allelic imbalance of chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 44:549–557PubMed

67.

Samowitz WS, Curtin K, Schaffer D, et al (2000) Relationship of Ki-ras mutations in colon cancer to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9:1193–1197PubMed

68.

Kressner U, Bjorheim J, Westring S (1998) ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34:518–521CrossRefPubMed

69.

Andreyev HJNA, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90:675–684CrossRefPubMed

70.

Elnatan J, Goh HS, Smith DR (1996) C-ki-ras activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 32A:491–497CrossRefPubMed

71.

Kastrinakis WV, Ramchurren N, Maggard M, Steele G, Summerhayes IC (1995) k-ras status does not predict successful hepatic resection of colorectal cancer metastasis. Arch Surg 130:9–14PubMed

72.

Finkelstein SD, Sayegh R, Bakker A, Swalsky P (1993) Determination of tumor aggressiveness in colorectal cancer by k-ras-2 analysis. Arch Surg 128:526–532PubMed

73.

Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M (1987) Detection of high incidence of k-ras oncogenes during human colon tumorigenesis. Nature 327:298–303

74.

Capella G, Cronauer-Mitra S, Peinado M, Perucho M (1991) Frequency and spectrum of mutations at codon 12 and 13 of the c-k-ras gene in human tumors. Environ Health Perspect 93:125–131PubMed

75.

Fearon E (1993) k-ras gene mutation as a pathogenic and diagnostic marker in human cancer. J Natl Cancer Inst 85:1978–1981PubMed

76.

Fearon ER, Cho KR, Nigro JM, et al (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49–56PubMed

77.

Cho KR, Fearon ER (1995) DCC: linking tumor suppressor genes and altered cell surface interactions in cancer? Eur J Cancer 31A:1055–1060

78.

Itoh F, Hinoda Y, Ohe M, et al (1993) Decreased expression of DCC mRNA in human colorectal cancers. Int J Cancer 53:260–263

79.

Lino H, Fukayama M, Maeda Y, et al (1994) Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential. Cancer 73:1324–1331PubMed

80.

Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK (1995) The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene 10:1581–1586PubMed

81.

Jernvall P, Mäkinen MJ, Karttunen TJ, Mäkelä J, Vihko P (1999) Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 79:903–908

82.

Carethers JM, Hawn MT, Greenson JK, Hitchcock CL, Boland CR (1998) Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 114:1188–1195PubMed

83.

Martinez-Lopez E, Abad A, Font A, et al (1998) Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 114:1180–1187PubMed

84.

Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16:427–433

85.

Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196–1206CrossRefPubMed

86.

Fazeli A, Dickinson SL, Hermiston ML, et al (1997) Phenotype of mice lacking functional deleted in colorectal cancer (DCC) gene. Nature 386:796–804

87.

Gotley DC, Reeder JA, Fawcett J, et al (1995) The deleted in colorectal cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene 13:787–795

88.

Hahn SA, Schutte M, Shamshul Hoque ATMS, et al (1996) DPC4: a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353PubMed

89.

Eppert K, Scherer SW, Ozcelik H, et al (1996) MADR2 maps to 18q21 and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543–552

90.

Sun XF, Rütten S, Zhang H, Nordenskjöld B (1999) Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol 17:1745PubMed

91.

Halling KC, French AJ, McDonnell SK, et al (1999) Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 15:1295–1303CrossRef

92.

Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H, Furukawa K (1998) Reduced expression of deleted colorectal carcinoma protein in established colon cancers. Br J Cancer 77:466–471

93.

Reymond MA, Dworak O, Remke S, Hohenberger W, Kirchner T, Köckeling F (1998) DCC protein as a predictor of distant metastases after curative surgery for rectal cancer. Dis Colon Rectum 41:755–760PubMed

94.

Cohn KH, Ornstein DL, Wang F, et al (1997) The significance of allelic deletions and aneuploidy in colorectal carcinoma. Cancer 79:233–244CrossRefPubMed

95.

Shibata D, Reale MA, Lavin P, et al (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727–1735PubMed

96.

Kato M, Ito Y, Kobayashi S, Isono K (1996) Detection of DCC and ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 77:1729–1735PubMed

97.

Young J, Buttenshaw R, Butterworth L, et al (1994) Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers. Oncogene 9:1053–1056PubMed

98.

Beverley SM, Ellenberger TE, Cordingly JS (1984) Primary structure the gene encoding the bifunctional dihydrofolate reduction-thymidylate synthase of Leishmania major. Proc Natl Acad Sci USA 83:2584–2589

99.

Conrad AH, Ruddle FH (1972) Regulation of thymidylate synthase activity in cultured mammalian cells. J Cell Sci 10:471–486PubMed

100.

Aschele C, Sobrero A, Faderan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-Fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855–1864PubMed

101.

Copur S, Aiba K, Drake JC, et al (1995) Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49:1419CrossRefPubMed

102.

Leichman L, Lenz HJ, Leichman CG, et al (1995) Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur J Cancer 31:1306–1310CrossRef

103.

YamachikaT, Nakanishi H, Inada KI, Tsukamoto T, Kato T, Fukushima M, et al (1998) A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82:70–77CrossRefPubMed

104.

Edler D, Kressner U, Ragnhammar, Johnston PG, Magnusson I, Glimelius B, et al (2000) Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 6:488–492PubMed

105.

Cascinu S, Graziano F, Valentini, Catalano V, Giordani P Stacciolo MP, et al (2001) Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 12:239–244CrossRefPubMed

106.

Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A (2000) Thymidylate synthase protein expression in primary colorectal cancer compared with corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6:4797–4802PubMed

107.

Cascinu S, Catalano V, Aschele C, Barni S, Debernadis D, Gallo L, et al (2000) Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann Oncol 11:1053–1056CrossRefPubMed

108.

Van Triest B, Pinedo HM, Blaauwgeers JLG, van Diest PJ, Schoenmakers PS, Voorn DA, et al (2000) Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063–1072PubMed

109.

Edler D, Hallström M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2000) Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease free-survival and overall survival in rectal cancer. Clin Cancer Res 6:1378–1384PubMed

110.

Aschele C, Debernardis D, Tunesi G, Bandelloni R, Cascinu S, Catalano V, et al (2000) Schedule-dependent correlation between the level of thymidylate synthase (TS) protein expression and clinical response to different 5-fluorouracil (5-FU) regimens in advanced colorectal cancer. Proc Am Soc Clin Oncol 19:251a

111.

Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, et al (2000) Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560–567

112.

Davies MM, Johnston PG, Kaur S, Allen-Mersh TG (1999) Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 5:325–328PubMed

113.

Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, et al (1999) Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17:1760–1772PubMed

114.

Cascinu S, Aschele C, Barni S, Debernadis D, Baldo C, Tunesi G, et al (1999) Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5:1996–1999PubMed

115.

Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75:903–909

116.

Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark M, Drake JC, et al (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640–2647PubMed

117.

Lenz H-J, Hayashi K, Solonga D, Danenberg KD, Danenberg PV, Metzger R, et al (1998) P53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243–1250PubMed

118.

Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223–3229PubMed

119.

Kornmann M, Link KH, Lenz H-J, Pillasch J, Metzger R, Butzer U, et al (1997) Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 118:29–35CrossRef

120.

Gorlick R, Metzger R, Danenberg KD, Solonga D, Miles JS, Longo GSA, et al (1998) Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol 16:1465–1469

121.

Sanguedolce R, Vultaggio G, Sanguedolce F, Modica G, Li Volsi F, Diana G, et al (1998) The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18:1515–1520PubMed

122.

Moghaddam A, Zang HAT, Fan TP, et al (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:988–1002PubMed

123.

Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, et al (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110–1117PubMed

124.

Metzger R, Danenberg K, Leichman CG, Solonga D, Schwartz EL, Wadler S, et al (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371–2376PubMed

125.

Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, et al (2000) Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer 88:42–49CrossRefPubMed

126.

Naguib FNM, El Kouni AM, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic tissues. Cancer Res 45:5405PubMed

127.

Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203–2206PubMed

128.

Solonga D, Danenberg KD, Johnson M, et al (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327PubMed

129.

Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260:812–816PubMed

130.

Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M, et al (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561PubMed

131.

Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Järvinen H, et al (1993) Genetic mapping of a locus predisposing to human colorectal cancer. Science 260:810–812PubMed

132.

Aaltonen LA, Peltomaki P, Mecklin JP, Järvinen H, Jass JR, Green JS, et al (1994) Replication errors in benign and malignant tumors from hereditary non-polyposis colorectal cancer patients. Cancer Res 54:1645–1648PubMed

133.

Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkänen L, et al (1993) Genomic instability in colorectal cancer: relationship of clinicopathological variables and family history. Cancer Res 53:5849–5852PubMed

134.

Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:816–819PubMed

135.

Kim H, Jen J, Vogelstein B, Hamilton SR (1994) Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145:148–156PubMed

136.

Möslein G, Testet DJ, Lindor NM, Honchel R, Cunningham JM, French AJ (1996) Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 5:1245–1252PubMed

137.

Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104:1535–1549PubMed

138.

Guidoboni M, Gafà R, Viel A, Doglioni C, Russo A, Santini A, et al (2001) Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 159:297–304PubMed

139.

Ward R, Meagher A, Tomlinson I, O'Connor T, Norrie M, Wu R, et al (2001) Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 48:821–829PubMed

140.

Gafà R, Maestri I, Matteuzzi M, Santini A, Ferretti S, Cavazzini L, et al (2000) Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 89:2025–2037CrossRefPubMed

141.

Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL (2000) Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87:1197–1202CrossRefPubMed

142.

Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H (2000) Microsatellite instability as a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119:921–928PubMed

143.

Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745–1750PubMed

144.

Gonzalez-Garcia I, Moreno V, Navarro M, Marti-Rague J, Marcuello E, Benasco C, et al (2000) Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst 92:544–549CrossRefPubMed

145.

Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69–77PubMed

146.

Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Chien CT, Wang SM (1999) Clinicopathological and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection. Hepatogastroenterology 46:883–890

147.

Johannsdottir JT, Bergthorsson JT, Gretarsdottir S, Kristjansson AK, Ragnarsson G, Jonasson JG, et al (1999) Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicopathological variables. Anticancer Res 19:1821–1826PubMed

148.

Jernvall P, Mäkinen MJ, Karttunen TJ, Mäkelä J, Vihkoo P (1999) Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer 35:197–201CrossRefPubMed

149.

Salahshor S, Kressner U, Fischer H, Lindmark G, Glimelius B, Pahlman L, et al (1999) Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 81:190–193CrossRefPubMed

150.

Feeley KM, Fullard JF, Heneghan MA, Smith T, Maher M, Murphy RP, et al (1999) Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol 188:14–17CrossRefPubMed

151.

Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, et al (1996) Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12:2641–2649PubMed

152.

Schmoll HJ, Büchele T, Grothey A, Dempke W (1999) Where do we stand with 5-FU? Semin Oncol 26:589–605

Titel: Molecular lesions in colorectal cancer: impact on prognosis?
Original data and review of the literature
verfasst von: B. Klump
O. Nehls
T. Okech
C.-J. Hsieh
V. Gaco
F. S. Gittinger
M. Sarbia
F. Borchard
A. Greschniok
H. H. Gruenagel
R. Porschen
M. Gregor
Publikationsdatum: 01.01.2004
Verlag: Springer-Verlag
Erschienen in: International Journal of Colorectal Disease / Ausgabe 1/2004
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-003-0499-7

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2004

A novel aspartate protease gene, ALP56, is related to morphological features of colorectal adenomas

Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer

Dynamic transperineal ultrasound vs. defecography in patients with evacuatory difficulty: a pilot study

Increased expression of nuclear factor-κB/RelA is correlated with tumor angiogenesis in human colorectal cancer

DNA variants in the ATM gene are not associated with sporadic rectal cancer in a Norwegian population-based study

Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum

Update Chirurgie